BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
BioStem Technologies (OTC: BSEM), a leading medtech company specializing in placental-derived allografts for advanced wound care, has announced it will release its second quarter 2024 financial results on Monday, August 12, 2024, after market close. The company will host a conference call and webcast at 4:30 PM ET to discuss the results.
The webcast will feature an overview of the quarter from CEO Jason Matuszewski and CFO Michael Fortunato. Interested parties can register for the event through the provided link. The live and archived webcast will also be available on the BioStem Technologies website under the Investors section.
BioStem Technologies (OTC: BSEM), un'azienda medtech leader specializzata in allograft derivati dalla placenta per la cura avanzata delle ferite, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il lunedì 12 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call e webcast alle 16:30 ET per discutere i risultati.
Il webcast presenterà una panoramica del trimestre a cura del CEO Jason Matuszewski e del CFO Michael Fortunato. Le parti interessate possono registrarsi per l'evento tramite il link fornito. Il webcast dal vivo e l'archivio saranno disponibili anche sul sito web di BioStem Technologies nella sezione Investitori.
BioStem Technologies (OTC: BSEM), una empresa de tecnología médica líder especializada en injertos alogénicos derivados de placenta para el cuidado avanzado de heridas, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el lunes 12 de agosto de 2024, después del cierre del mercado. La empresa realizará una conferencia telefónica y webcast a las 4:30 PM ET para discutir los resultados.
El webcast contará con un resumen del trimestre por parte del CEO Jason Matuszewski y el CFO Michael Fortunato. Las partes interesadas pueden registrarse para el evento a través del enlace proporcionado. El webcast en vivo y el archivo también estarán disponibles en el sitio web de BioStem Technologies en la sección de Inversionistas.
BioStem Technologies (OTC: BSEM), 고급 상처 치료를 위한 태반 유래 동종 이식편을 전문으로 하는 선도적인 의료 기술 회사가 2024년 2분기 재무 결과를 2024년 8월 12일 월요일, 시장 종료 후 발표할 예정이라고 발표했습니다. 회사는 결과에 대해 논의하기 위해 동부 표준시 기준 오후 4시 30분에 전화 회의 및 웹캐스트를 주최할 것입니다.
웹캐스트에서는 CEO Jason Matuszewski와 CFO Michael Fortunato가 분기 개요를 제공할 것입니다. 관심 있는 분들은 제공된 링크를 통해 이벤트에 등록할 수 있습니다. 실시간 및 아카이브 웹캐스트는 BioStem Technologies 웹사이트의 투자자 섹션에서도 확인할 수 있습니다.
BioStem Technologies (OTC: BSEM), une entreprise leader en technologie médicale spécialisée dans les allogreffes dérivées du placenta pour les soins avancés des plaies, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le lundi 12 août 2024, après la clôture du marché. L'entreprise organisera un appel conférence et un webcast à 16h30 ET pour discuter des résultats.
Le webcast comprendra un aperçu du trimestre par le PDG Jason Matuszewski et le directeur financier Michael Fortunato. Les parties intéressées peuvent s'inscrire à l'événement via le lien fourni. Le webcast en direct et l'archive seront également disponibles sur le site Web de BioStem Technologies dans la section Investisseurs.
BioStem Technologies (OTC: BSEM), ein führendes Medizintechnikunternehmen, das auf placentabezogene Allografts für fortgeschrittene Wundversorgung spezialisiert ist, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Montag, den 12. August 2024, nach Marktabschluss veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET eine Konferenzschaltung und ein Webcast veranstalten, um die Ergebnisse zu besprechen.
Der Webcast wird einen Überblick über das Quartal von CEO Jason Matuszewski und CFO Michael Fortunato bieten. Interessierte Parteien können sich über den bereitgestellten Link für die Veranstaltung registrieren. Der Live- und Archiv-Webcast wird ebenfalls auf der Website von BioStem Technologies im Bereich Investoren verfügbar sein.
- BioStem Technologies is proactively communicating its financial results to investors
- The company is providing multiple ways for investors to access the quarterly results and discussion
- None.
Conference Call and Webcast to be held at 4:30 PM ET
POMPANO BEACH, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading medtech company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, announced today that it will release its second quarter 2024 financial results after the market close on Monday, August 12, 2024. The company will also host a conference call and webcast at 4:30 PM ET to discuss the results.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Michael Fortunato, CFO. To register for the event, please click HERE.
Conference Call & Webcast Information:
- USA / International Toll: +1 (646) 307-1963
- USA - Toll-Free: (800) 715-9871
- Canada – Toronto: (647) 932-3411
- Canada - Toll-Free: (800) 715-9871
- Webcast Link: https://events.q4inc.com/attendee/133546543
The live and archived webcast of the call will also be available on the BioStem Technologies website under the Investors section or by clicking HERE.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate", "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
FAQ
When will BioStem Technologies (BSEM) release its Q2 2024 financial results?
What time is BioStem Technologies' (BSEM) Q2 2024 earnings call scheduled for?
Who will be presenting during BioStem Technologies' (BSEM) Q2 2024 earnings call?
How can investors access BioStem Technologies' (BSEM) Q2 2024 earnings call?
